Internal Medicine, Medical Oncology · Seattle, WA
NPI
1285724138
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
University of Washington Medical Ctr, 1959 NE Pacific St
Seattle, WA, 98195
Phone (206) 288-1000
Groups this clinician bills Medicare through
Medicare paid, 2024
$26K
291 services
Medicare patients, 2024
89
Average age 73
Drug cost, 2024
$446K
42 prescriptions
Company payments, 2025
$210K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Bart L Scott was code 99214 (office e&m - established), 78 times for 52 patients. In total Bart L Scott billed 291 services in 12 codes, and Medicare paid $26K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-11-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 78 | 52 | $75.26 | $5,870 |
| 99215 Office E&M - Established | Office | 58 | 32 | $125.20 | $7,262 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 23 | 22 | $14.64 | $337 |
| 99205 Office E&M - New | Office | 11 | 11 | $149.89 | $1,649 |
By year: 2022 $18K for 209 services; 2023 $25K for 261 services; 2024 $26K for 291 services.
Medicare prescription drug claims, 2024
In 2024, the drug Bart L Scott prescribed most often to Medicare patients was Inrebic (Fedratinib Dihydrochloride), with 15 prescriptions and refills. In total Bart L Scott wrote 42 Medicare prescriptions that cost $446K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Inrebic Fedratinib Dihydrochloride | 15 | 15 | Under 11 | $354K |
| Hydroxyurea Generic | 11 | 15 | Under 11 | $134 |
Brand drugs: 21 claims; generic drugs: 21 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Bart L Scott $210K ($210K in general payments such as food, travel and fees) from 13 companies. The largest payer was Alexion Pharmaceuticals, Inc. with $62K.
| Company | Payments | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. AZN | 54 | $62K |
| Incyte Corporation INCY | 52 | $52K |
| Geron Corporation GERN | 27 | $36K |
| E.R. Squibb & Sons, L.L.C. BMY | 10 | $21K |
| Taiho Oncology, Inc. 4578.T | 13 | $18K |
| Syndax Pharmaceuticals, Inc. SNDX | 6 | $11K |
| Sobi, Inc SOBI.ST | 7 | $4,565 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $3,188 |
| Apellis Pharmaceuticals, Inc. APLS | 2 | $2,858 |
| Celgene Corporation BMY | 3 | $292 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.